Puerto Rico BioBank Core

点击翻译按钮获取中文摘要

ABSTRACT The Puerto Rico BioBank (PRBB) Shared Resource of the Ponce Health Sciences University-Moffitt Cancer Center (PHSU-MCC) Partnership collects, processes, annotates, stores, and distributes biospecimens and clinical-demographic data for investigator-initiated translational cancer research. As of August 2022, the PRBB has consented 4,097 subjects representing 42 different cancer types and healthy individuals. From these subjects, 1,899 clinical history and demographic surveys were completed and 8,453 biospecimens were collected. Tissues, derivative analytes (e.g., DNA/RNA), data, and tissue microarrays have been distributed to research projects supporting publications and grant submissions. The PRBB contributed to the development of a Biobanking clerkship for medical students in collaboration with the Research Education Core (REC) and contributed to education efforts in H/L communities in both Tampa and Ponce in collaboration with the Outreach Core (OC). Together with the Quantitative Sciences Core (QSC), the PRBB has consented 142 H/L patients to the ORIEN-Avatar network (https://www.oriencancer.org) improving the representation of H/L tissues in this network, dedicated to accelerating the discovery of novel targeted cancer treatments, that is currently only 7.2%. The PRBB participates in international consortia including REBLAC (Latin American and Caribbean Biobanking network), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome), LAGENO-BC (Latin America Genomics of Breast Cancer Consortium), the Latino Colorectal Cancer Consortium (LC3), the Confluence Project for Breast Cancer Genetics. The objective of the PRBB is to address the critical unmet need in cancer health disparities of a lack of representation of H/L patients in comprehensive molecular datasets at levels that align with the prevalence of cancer in this population. The aims are: 1) Support research projects by targeted recruitment of patients of selected cancer types along with non-cancer controls. Recruitment is both broad to build a comprehensive database for future projects and focused on the currently proposed full research projects in prostate and ovarian cancer. We will continue to optimize the logistics of patient education and consenting at collaborating physician’s offices and San Lucas Hospital (SLH) and by maintaining constant contact with Project PIs. 2) Support research by developing innovative resources and services. We will focus on developing new research resources and services that can be rapidly accessed by researchers. This includes building well-annotated tissue microarrays representing cancer types that significantly impact H/Ls (prostate, ovarian), expanding molecular phenotyping (exomeSeq, RNAseq, ancestry) in collaboration with ORIEN, tapping into the potential for identifying clinical trials that are matched to a patient’s molecular profile, and leverage our emerging expertise in organoid and patient-derived xenografts models to support projects. 3) Collaborate with partnership components in education, outreach, and community education on the importance of tissue donation, and improving data availability with the QSC.